SU2C Catalyst® Research Projects Supported by Genentech

 

From: "Young, Benjamin" <benjamin.young [at] aacr.org> on behalf of SU2C <su2c [at] aacr.org>
Date: Friday, August 24, 2018 at 10:37 AM
Subject: Exciting New Grant Opportunity: SU2C Catalyst® Research Projects Supported by Genentech

 

 

cid:image001.jpg@01D43B8F.2860ED70

 

Dear Colleagues,

 

We are excited to share with you that the American Association for Cancer Research (AACR) is now accepting submissions for Stand Up To Cancer (SU2C) Catalyst® Genentech-Supported projects, which will offer up to $3M over 3 years for immune therapy, biomarker-focused clinical trials involving solid tumors (alectinib, entrectinib, ipatasertib and atezolizumab) and hematologic malignancies (polatuzumab, venetoclax). Clinical trials can utilize Genentech molecules alone or in combination with other therapies.

 

Proposal Submission Deadline: October 22, 2018 at Noon U.S. Eastern Time

 

Apply Now: https://proposalcentral.altum.com/default.asp

 

Learn More: https://www.aacr.org/Catalyst_Genentech

(Please note that you will not be able to view the grant related information on proposalCENTRAL until Monday, August 27, 2018.)

 

If you have any questions, please feel free to email us at su2c [at] aacr.org ().